What is Applied Proteomics?
Applied Proteomics, Inc. is a biotechnology firm dedicated to developing and commercializing advanced protein-based diagnostic tests. Their flagship product, the SimpliPro Colon Test, is designed for healthcare providers to assess colorectal wellness by evaluating 11 protein markers associated with the risks of esophageal cancer and advanced adenoma. This comprehensive blood test aims to improve patient adherence to screening procedures by integrating easily into routine medical examinations. The company's focus on enhancing cancer risk assessment through sophisticated protein analysis positions it as a key player in the diagnostic technology sector, serving healthcare providers seeking cutting-edge tools.
How much funding has Applied Proteomics raised?
Applied Proteomics has raised a total of $54.5M across 3 funding rounds:
Series A
$4M
Series B
$22.5M
Series C
$28M
Series A (2007): $4M, investors not publicly disclosed
Series B (2012): $22.5M led by Domain Associates and Vulcan Capital Management
Series C (2013): $28M supported by Genting Berhad, Vulcan Capital Management, and Domain Associates
Key Investors in Applied Proteomics
Genting Berhad
Genting Group, founded in 1965 and headquartered in Kuala Lumpur, Malaysia, is a diversified conglomerate involved in various sectors, including hospitality and leisure. Their investment in Applied Proteomics suggests a strategic interest in expanding their portfolio into the healthcare and biotechnology sectors.
Domain Associates
DomainVC is a venture capital firm established in 1985 with a specialization in biotech investments. With a history of backing numerous biopharmaceutical, device, and diagnostic companies, their participation indicates a strong belief in Applied Proteomics' potential within the life sciences industry.
Vulcan Capital Management
Vulcan Capital Management is a private equity firm focusing on diverse investment opportunities, including those in the energy sector. Their involvement with Applied Proteomics highlights a strategic diversification into the high-growth biotechnology and diagnostics market.
What's next for Applied Proteomics?
With the recent major strategic investment, Applied Proteomics is poised for significant expansion and further development of its diagnostic technologies. The substantial enterprise-level capital infusion suggests a focus on scaling operations, enhancing market penetration, and potentially broadening the application of their protein marker analysis to other disease areas. This strategic financing will likely accelerate the company's mission to provide healthcare professionals with more accurate and accessible tools for early disease detection, reinforcing its position in the competitive biotech and diagnostics landscape.
See full Applied Proteomics company page
